Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 77 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

10 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed trials have results

Key Signals

33 recruiting

Enrollment Performance

Analytics

Phase 2
26(44.1%)
N/A
19(32.2%)
Phase 3
7(11.9%)
Phase 4
3(5.1%)
Phase 1
2(3.4%)
Early Phase 1
2(3.4%)
59Total
Phase 2(26)
N/A(19)
Phase 3(7)
Phase 4(3)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (77)

Showing 20 of 77 trials
NCT07013461Recruiting

International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer

Role: collaborator

NCT05213884Phase 2Completed

The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

Role: lead

NCT07543848Phase 2Not Yet Recruiting

A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer

Role: lead

NCT07425795Phase 2Recruiting

Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer

Role: lead

NCT06059261Phase 2Recruiting

Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

Role: lead

NCT05524168Phase 2Active Not Recruiting

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

Role: collaborator

NCT06498154Phase 2Recruiting

Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy

Role: collaborator

NCT07248696Not ApplicableActive Not Recruiting

Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial

Role: lead

NCT07248670Phase 3Active Not Recruiting

Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC

Role: lead

NCT07249957Not ApplicableNot Yet Recruiting

Reducing Radiation Target Volume for Stage IIb Cervical Cancer

Role: lead

NCT07217600Phase 4Recruiting

Ondansetron Orodispersible Film for Vomiting Prevention in Pediatric Radiotherapy

Role: lead

NCT04555226Not ApplicableRecruiting

The Efficacy of Lymph Node Dissection for Stage IIICr of Cervical Cancer(CQGOG0103)

Role: lead

NCT05147844Phase 2Recruiting

Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Role: collaborator

NCT05044871Phase 2Completed

Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer

Role: collaborator

NCT06078930Recruiting

Development of Novel Gastric Cancer Screening and Diagnosis Technologies Using Tongue Imaging and Study of Tongue Image Changes Mechanisms

Role: collaborator

NCT06981858Phase 2Not Yet Recruiting

A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

Role: lead

NCT06786780Phase 2Enrolling By Invitation

Establishment and Validation of Prediction Model of Simultaneous Chemoradiotherapy for Cervical Cancer Organoids

Role: lead

NCT04516616Phase 2Active Not Recruiting

Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer

Role: collaborator

NCT06863831Not ApplicableEnrolling By Invitation

A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC

Role: collaborator

NCT05440357Recruiting

Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world Study

Role: collaborator